Atea Pharmaceuticals, Inc.

For the period ended Mar 31, 2026. Filed May 12, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 12, 2026

AVIR$4.41+2.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

	March 31,2026	December 31,2025
Assets
Current assets
Cash and cash equivalents	$79,317	$95,713
Marketable securities	176,689	206,117
Prepaid expenses and other current assets	7,191	9,161
Total current assets	263,197	310,991
Property and equipment, net	353	457
Other assets	3,048	3,136
Operating lease right-of-use assets, net	478	634
Total assets	$267,076	$315,218
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable	$9,446	$12,945
Accrued expenses and other current liabilities	23,287	25,996
Current portion of operating lease liabilities	634	843
Total current liabilities	33,367	39,784
Commitments and contingencies (see Note 11)
Stockholders’ equity:
Preferred stock, $0.001 par value per share; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	—	—
Common stock, $0.001 par value; 300,000,000 shares authorized; 80,027,099 and 78,126,796 shares issued and outstandingas of March 31, 2026 and December 31, 2025, respectively	80	78
Additional paid-in capital	801,735	797,751
Accumulated other comprehensive (loss) gain	(97)	174
Accumulated deficit	(568,009)	(522,569)
Total stockholders’ equity	233,709	275,434
Total liabilities and stockholders’ equity	$267,076	$315,218

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.